28
Oct
2025

Beijing Minhai Biotechnology Co., Ltd

Exhibitor at CPHI Frankfurt 2025 stand 4.1B30, Finished Dosage Formulations
About Us

A leading pharmaceutical company specializing in vaccine development and manufacturing.13-valent pneumococcal conjugate vaccine,
23-valent pneumococcal Polysaccharideconjugate vaccine,
Hepatisit B vaccine,
Varicella vaccine,
Rabies vaccine,
DTaP-Hib
Hib,
DTaP,
Penta valent vaccine,
IPV vaccine
TT vaccine
MMR vaccine,
4-valent influenza vaccine,



Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2023
    On CPHI since
  • 1
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Frankfurt 2025
  • 28 Oct 2025 - 30 Oct 2025
  • Messe, Frankfurt
  • Visit us at stand 4.1B30, Finished Dosage Formulations

Products Featured at CPHI Frankfurt 2025

  • 13-valent pneumococcal conjugate vaccine

    Product 13-valent pneumococcal conjugate vaccine

    Protects against infectious diseases caused by pneumococcal types 1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F and 23F, including pneumonia, meningitis, otitis media, bacteremia.

  • Recombinant Hepatitis B vaccine (Saccharomyces cerevisiae

    Product Recombinant Hepatitis B vaccine (Saccharomyces cerevisiae

    Recombinant Hepatitis B vaccine is a preparation made of purified hepatitis B surface antigen (HBsAg) expressed by the recombinant Saccharomyces cerevisiae. After purification of HBsAg, a quantity of aluminum adjuvant is added to make the vaccine. The vaccine is a milky-white suspension with stratified pre...
  • Varicella Vaccine, Live

    Product Varicella Vaccine, Live

    It can stimulate the body to produce immunity against varicella-zoster virus, which is used to prevent varicella.